158 related articles for article (PubMed ID: 1604221)
1. [Comparative effects of sodium fluoride and hormonal replacement therapy on bone metabolism in osteoporotic women with high fracture risk. Results of monitoring for 2 years].
Pouillès JM; Trémollières F; Ribot C
Rev Rhum Mal Osteoartic; 1992 Feb; 59(2):103-13. PubMed ID: 1604221
[TBL] [Abstract][Full Text] [Related]
2. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
[TBL] [Abstract][Full Text] [Related]
4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic concepts in the treatment of postmenopausal osteoporosis].
Leidig-Bruckner G; Ziegler R
Ther Umsch; 1994 Nov; 51(11):737-47. PubMed ID: 7839332
[TBL] [Abstract][Full Text] [Related]
6. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
Celi M; Letizia C; Ragno A; Minisola S; D'Erasmo E; Mazzuoli GF
Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970
[TBL] [Abstract][Full Text] [Related]
7. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous hip fractures in fluoride-treated patients: potential causative factors.
Gutteridge DH; Price RI; Kent GN; Prince RL; Michell PA
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S205-15. PubMed ID: 2339631
[TBL] [Abstract][Full Text] [Related]
9. Fluoride treatment of postmenopausal osteoporosis: age, renal function, and other clinical factors in the osteogenic response.
Murray TM; Harrison JE; Bayley TA; Josse RG; Sturtridge WC; Chow R; Budden F; Laurier L; Pritzker KP; Kandel R
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S27-35. PubMed ID: 2339633
[TBL] [Abstract][Full Text] [Related]
10. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
11. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
12. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
Bunyavejchevin S; Limpaphayom KK
J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
[TBL] [Abstract][Full Text] [Related]
13. Fluoride therapy for osteoporosis promotes a progressive increase in spinal bone density.
Farley SM; Libanati CR; Mariano-Menez MR; Tudtud-Hans LA; Schulz EE; Baylink DJ
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S37-42. PubMed ID: 2339634
[TBL] [Abstract][Full Text] [Related]
14. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
15. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
16. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
17. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
Delmas PD; Dupuis J; Duboeuf F; Chapuy MC; Meunier PJ
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S143-7. PubMed ID: 2339624
[TBL] [Abstract][Full Text] [Related]
18. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.
Garnero P; Delmas PD
J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):50-63. PubMed ID: 15615078
[TBL] [Abstract][Full Text] [Related]
19. [Indications and limitations of non-hormonal treatments of osteoporosis].
Avouac B
Rev Fr Gynecol Obstet; 1993; 88(7-9):419-23. PubMed ID: 8235256
[TBL] [Abstract][Full Text] [Related]
20. Hormone replacement therapy increases trabecular and cortical bone density in osteoporotic women.
Bagur A; Wittich A; Ghiringhelli G; Vega E; Mautalen C
Medicina (B Aires); 1996; 56(3):247-51. PubMed ID: 9035480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
